Chardan raised the firm’s price target on Palvella Therapeutics (PVLA) to $210 from $174 and keeps a Buy rating on the shares. The company announced “excellent” data for topical Qtorin rapamycin in the Phase III SELVA trial in microcystic lymphatic malformation, the analyst tells investors in a research note. Chardan increased its probability of success for microcystic lymphatic malformation to 90% from 70%, and to 65% from 55% in cutaneous venous malformations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Ligand price target raised to $239 from $231 at H.C. Wainwright
- Palvella Therapeutics price target raised to $250 from $180 at Stifel
- Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright
- Palvella Reports Positive Phase 3 Data for QTORIN Gel
- Palvella Reports Positive Phase 3 Data for QTORIN